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Abstract 
   Chronic kidney disease (CKD) is a common cause of morbidity and mortality in cats.  
The purpose of this study was to investigate the effects of Chinese rhubarb (Rheum officinale) 
supplementation on the progression of feline CKD. 
 
   Cats with stable IRIS stage II or III CKD and without certain comorbidities were 
included in the study.  Cats were randomly divided into 3 treatment groups and administered 
Chinese rhubarb extract (Group 1, Rubenal®, Vetoquinol, Forth Worth, TX; 75 mg tablet by 
mouth every 12 h), benazepril as a positive control (Group 2, 0.5 mg/kg by mouth every 24 h), or 
both (Group 3).  Cats were fed a commercial renal specific diet and enteric phosphate binder as 
appropriate.  Body weight, laboratory data, and blood pressure were recorded every 3 months. 
 
   Variables between groups at enrollment and within groups over visits were compared 
with ANOVA and repeated measures ANOVA, respectively.  A treatment by visit interaction 
term was included in all repeated measures models.  Significance was set at p ≤ 0.05. 
 
   Except for body weight there was no significant differences between treatment groups 
at enrollment.  There was no significant change in body weight, hematocrit (Hct), UPC, serum 
creatinine, or systemic blood pressure over time as compared to baseline within any group.   
There was no significant difference between groups over time in regards to change in body 
weight, Hct, UPC, serum creatinine, or systemic blood pressure.  The treatment by time 
interaction was non-significant in all models.  
 
   Based on easily measured clinical parameters, this study failed to detect a significant 
difference in cats administered a Chinese rhubarb supplement, benazepril, or both. 
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Chapter 1 - Review of Feline Chronic Kidney Disease 
 Clinical Importance 
Chronic kidney disease (CKD) is one of the most common killers of cats and prevalence 
increases with age.
1,2
  It has been estimated that over 30% of cats over the age of 15 are afflicted 
with CKD.
2
  In a large epidemiologic study of feline patients presented to a primary care 
veterinarian, CKD was diagnosed in 1.9% of all cats.
3
  It is important to note that the median age 
of cats in the aforementioned study was 4.3 years.  Feline CKD has worldwide importance as the 
most common cause of all deaths in insured cats in Sweden are due to renal and ureteral disease 
(16%).
1
  In the UK, 30% of non-azotemic, geriatric cats followed for a minimum of 12 months 
became azotemic.
4
 
 Clinical Stage 
In order to facilitate communication between veterinarians concerning the appropriate 
treatment of feline CKD and to standardize classifications for scientific studies, a staging scheme 
has been developed by the International Renal Interest Society (IRIS) (Appendix A).
5
  Staging is 
based on fasted serum/plasma creatinine concentration in an adequately hydrated patient.  In 
addition the presence or lack of proteinuria and systemic hypertension are noted as sub-stages 
(Appendix A).
5
  
 
 Current Treatment 
Treatment of feline CKD can be medical or in the form of renal replacement therapy (i.e.  
hemodialysis or renal transplant).  The goals of medical management are to slow the progression 
of kidney disease and ideally prevent or at least detect and treat the consequences of declining 
renal function that lead to a decreased quality of life. Current medical treatment of CKD includes 
dietary modification and long term monitoring and treatment as appropriate of proteinuria, 
systemic hypertension, urinary tract infections, acid-base and electrolyte abnormalities, anemia, 
gastrointestinal ulcer and erosion, malnutrition, and dehydration.   
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Generally, commercial renal specific diets contain less protein, phosphorous, and sodium 
and more omega-3 fatty acids and potassium as compared to conventional diets.
6-8
  Feeding a 
renal specific diet has been shown to increase survival and decrease uremic episodes in feline 
CKD.
9-11
  Elliott et al. found that cats fed a renal diet had a mean survival of 633 days as 
compared to cats not fed a renal diet that survived an average of 264 days.
10
  Ross et al. showed 
that cats fed a renal diet had fewer uremic episodes (clinically ill with an increase in creatinine 
and the lack of other detectable disease) (0%) as compared to cats not fed a renal diet (26%).
9
  In 
the same study, renal-related death was also significantly lower in the cats fed a renal diet (0%) 
as compared to cats not fed a renal diet (21.7%) over a 12 to 24 month period.
9
  In a third study, 
Plantinga et al. showed that cats fed a renal diet had a median survival of 16 months as compared 
to cats that ate a conventional diet who survived a median of 7 months.
11
  Interestingly the diet 
that led to the longest median survival (23 months) contained the highest level of omega-3 fatty 
acids.
11
   
 
As GFR decreases renal excretion of phosphorus also declines.  CKD is the most 
common cause of hyperphosphatemia in the cat.
12
  In a group of cats with various stages of CKD 
plasma phosphate concentrations were increased in 20%, 49%, and 100% of cats with mean 
plasma creatinine concentrations of 2.6, 3.6, and 10.3 mg/dL, respectively.
13
 The deleterious 
effects of hyperphosphatemia include secondary hyperparathyroidism and soft tissue 
mineralization.  Soft tissue mineralization could possibly contribute to the progression of CKD.  
Barber and Elliott found that 47% of cats with compensated CKD and 100% of cats with end 
stage CKD had increased parathyroid hormone concentrations.
13
    Cats with partial renal 
ablation fed a phosphorous restricted diet had less severe renal mineralization, fibrosis, and 
inflammation as compared to cats fed a maintenance diet.
14
  King et al. found a significant 
association between plasma phosphate concentration and shorter survival times.
15
  In the 
aforementioned study plasma phosphate also correlated with plasma creatinine concentrations 
making it a dependent risk factor for survival time.
15
  In another study with each 1 unit increment 
(mg/dL) increase in phosphorous at the time of diagnosis there was an 11.8% increase in the risk 
of death.
16
  The most effective way to prevent hyperphosphatemia and hyperparathyroidism 
includes dietary phosphate restriction with or without an enteric phosphate binder.  Barber et al. 
demonstrated that feeding a diet with reduced phosphate content and in some cases in 
3 
 
combination with an enteric phosphate binder could normalize serum phosphorous and 
parathyroid hormone concentrations in cats with CKD.
17
  Interestingly a more recent study 
demonstrated the ability of an enteric phosphate binder to decrease serum phosphorous and 
parathyroid hormone concentrations in cats with reduced renal function fed a maintenance diet.
18
  
There are currently multiple enteric phosphate binders available, which have been recently 
reviewed.
12
  Administering calcitriol, in the absence of hypercalcemia, makes physiologic sense 
and has been advocated by some.  Unfortunately prospective studies investigating calcitriol 
supplementation have failed to show any significant effects on parathyroid hormone 
concentrations.
19
   
 
There is a small amount of evidence to suggest that administering an angiotensin 
converting enzyme inhibitor (ACEi) may help slow the progression of feline CKD.
20,21
  Cats that 
received 0.5-1 mg/kg/day of benazepril over a 6 month period were less likely to progress from 
stage II and III to stage IV CKD as compared to cats administered a placebo.
20
  In one study cats 
receiving benazepril at 1.0 mg/kg/day had a significant decrease in serum creatinine, which was 
not seen in the control group.
21
  A separate study failed to show a significant difference in 
survival (death or euthanasia due to to causes other than CKD are not considered) when 
benazepril was administered to cats with CKD although the drug was well tolerated and cats with 
a UPC ≥1 had a significantly better appetite.22  Although prospective studies demonstrating the 
ability of an ACEi to prolong survival are lacking, there is strong evidence in humans and other 
species to support the use of an ACEi.
23-26
  Apparently, the beneficial effects of RAAS inhibition 
go beyond simply decreasing proteinuria and normalizing systemic blood pressure.
27,28
    
Benazepril has been shown to significantly decrease proteinuria in cats.
22
  The presence and 
degree of proteinuria has consistently been shown to have prognostic importance in feline 
CKD.
4,15,29,30
  Syme et al. showed that cats with CKD and a UPC of 0.2-0.4 or >0.4 had a 2.9 and 
4.0 hazard ratio for death or euthanasia as compared to cats with CKD and a UPC <0.2, 
respectively.
29
 In agreement King et al. found that as the UPC increased above 0.2, survival time 
decreased.
15
  In addition in a third group of cats with CKD, an increased UPC was associated 
with death within one month.
31
  In non-azotemic geriatric cats that became azotemic over the 
subsequent 12 months, serum creatinine and either urine albumin or urine protein concentrations 
remained in the final statistical model as predictors of impending azotemia.
4
  The clinical 
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importance of proteinuria paired with the fact that ACEi decreases proteinuria
21
 may be the 
strongest argument for the use of an ACEi in feline CKD.   
 
The UPC is considered the gold standard in quantification of urine protein content as it 
correlates well with 24 hour urine protein excretion in normal and experimentally induced renal 
disease.
32
  It should be noted that the urine dipstick and sulfasalicylic acid assay have relatively 
low specificity and sensitivity, for detecting albuminuria, when interpreted in parallel or in 
series, respectively.
33
  Increasing the cutoff for a positive test result increases specificity but 
makes the sensitivity unacceptably low.
33
 Low grade proteinuria known as “microalbuminuria” 
will not be detected by the current methods of determining the UPC.  The clinical importance of 
microalbuminuria remains unknown.  It is yet to be determined if proteinuria is a marker for a 
more rapidly progressive renal pathology or if proteinuria itself contributes to declining renal 
function.  In other species there is much evidence to support the latter, which has been reviewed 
elsewhere.
34,35
 
 
At least 19% of cats with CKD have systemic hypertension.
36
  Systemic hypertension can 
lead to further renal damage in addition to other end organ damage.  Control of systemic 
hypertension has been shown to decrease proteinuria in cats with  CKD.
30
  In the same study it 
was found that the control of proteinuria and not systemic hypertension per se was significantly 
related to survival.
30
   The ACVIM Consensus Statement recommends antihypertensive therapy 
when the systolic blood pressure is >160 mmHg and/or the diastolic blood pressure is >100 
mmHg.
37
  Activation of the RAAS is one contributing factor to systemic hypertension in cats 
with CKD.
38
  In one study both enalapril and benazepril failed to completely inhibit the 
activation of RAAS and failed to normalize systolic blood pressure in 14/16 cats.
39
  Since an 
ACEi is commonly not effective at controlling systemic hypertension alone, an additional 
therapy such as a calcium channel blocker may be required. 
 
Urinary tract infections were identified in 16.9% and 22% of cats with CKD in two 
studies.
40,41
  Being female, Persian, and increasing age were associated with a positive urine 
culture.
40
  It was not uncommon for cats to lack clinical signs and urinalysis findings typically 
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associated with bacterial lower urinary tract infection.
41
  The only reliable means of detecting a 
bacterial infection in this subset of cats is a urine culture.   
 
Cats with CKD are at increased risk of developing hypokalemia (OR=14.4) as compared 
to cats with normal renal function.
42
  In the same study cats with severe hypokalemia (<3.0 
mEq/L) were 3.5 times more likely to have CKD than cats with moderate hypokalemia (3.1 – 4.1 
mEq/L).
42
  In a separate study cats with CKD excreted 2.5 times the amount of potassium in the 
urine as compared to normal cats.
43
  In this group of cats GFR and tubular reabsorption of 
potassium were decreased and the quantity of urine produced was increased as compared to 
normal cats.
43
  Hypokalemia due to increased urinary loss may be exacerbated by the fact that 
many cats with CKD are anorexic or hyporexic leading to decreased intake of dietary 
potassium.
15,44
   As kidney disease progresses the occurrence of hypokalemia decreases and the 
frequency of hyperkalemia increases.
15
  This is thought to be due to decreased urine production 
in end stage renal disease.
42
  Deleterious effects of hypokalemia include muscular weakness, 
functional ileus, cardiac arrhythmias, renal vasoconstriction leading to decreased GFR, and 
exacerbation of polyuria and polydipsia due to decreased responsiveness to anti-diuretic 
hormone. In the case of severe hypokalemia intravenous potassium supplementation in the form 
of potassium chloride is recommended.
45
  For long term maintenance therapy oral potassium 
gluconate may be administered as this is the most palatable potassium salt available.   
 
Anemia is a common hematologic finding in cats with CKD and increases in occurrence 
and severity as kidney function declines.
15,16,44
  The cause of anemia is multifactorial and 
includes the relative lack of erythropoietin, gastrointestinal blood loss, anemia of chronic 
disease, and shortened red blood cell lifespan.
46
   Gastrointestinal blood loss may be due to 
gastroduodenal ulceration or erosion, which is secondary to hypergastrinemia.
47
  In one study the 
prevalence of anemia ranged from 0% in cats without clinical signs (mostly IRIS Stage II) to 
65% in cats with end-stage CKD (IRIS Stage IV).
44
  Anemia in some studies has been shown to 
be a prognostic factor with cats that died within 1 month having a significantly lower 
hematocrit.
31
  Boyd et al. showed that the median survival of cats that became anemic (Hct 
<25%) and that underwent intervention for their anemia was 100 days and 25 days, 
respectively.
16
  Antacids in the form of H2-receptor antagonists or proton pump inhibitors are 
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indicated in the case of anemia or GI upset.  The lack of erythropoietin can be treated with 
recombinant human erythropoietin (r-HuEPO) or darbopoetin which will consistently increase 
RBC mass.
48
  Because both erythropoietin products are non-feline proteins, both may evoke anti-
erythropoietin antibodies.
48
  In one small study, 5 of 7 cats receiving r-HuEPO developed 
refractory anemia and 4 of those 5 cats had detectable anti-r-HuEPO antibodies at the onset of 
the refractory anemia.
48
  Erythropoietin therapy is generally instituted when the patient shows 
clinical signs of anemia.  The benefits of treating anemia must be greater than the risks 
associated with inducing anti-EPO antibodies.  According to the chronic hypoxia theory (see 
below) more aggressive treatment of anemia may be warranted.
49
 
 
Clinical dehydration was apparent in 10% of uremic cats and 73% of cats with end-stage 
CKD in one study.
44
  The prevalence of sub-clinical dehydration would be expected to be even 
higher.  Dehydration occurs when water consumption does not keep pace with polyuria.  
Dehydration causes pre-renal azotemia, which in addition to renal azotemia exacerbates the 
deleterious effects of uremia.  Some cats benefit from parenteral fluid supplementation and sub-
cutaneous fluid administration is commonly a feasible at-home treatment option.  An alternative 
option to sub-cutaneous fluid administration requires placing a feeding tube.  Esophagostomy or 
gastrostomy (e.g., percutaneous endoscopically guided) tubes are safe and simple to place and 
facilitate the administration of water and nutritional supplementation if needed.  In addition 
many medications can be administered via a feeding tube, which may improve owner 
compliance.   
 
Cats with an appropriate temperament and the absence of concurrent disease including 
cardiac, endocrine, and infectious disease(s) may be candidates for renal transplant.
50
  Following 
renal transplant, ongoing medical management including life-long immunosuppression to 
prevent allograft rejection is required. Due to stringent pre-operative patient screening and the 
relatively high monetary and time commitments required of the owner renal transplant is often 
not a feasible option.   
 
Intermittent hemodialysis is an alternative renal replacement therapy in acute and chronic 
kidney disease and has been described in 14 cats with CKD.
51
  Hemodialysis does improve 
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biochemical abnormalities but does not address the underlying cause of renal dysfunction.   For 
this reason except in some cases of “acute on chronic” renal failure, life-long treatment would be 
required.  Due to the small size of the domestic cat, performing hemodialysis is technically 
challenging with a substantial risk of various complications including; pulmonary edema, 
hypotension, disequilibrium, cardiopulmonary arrest, and seizures to name a few.
51
  Because of 
the need for ongoing therapy and associated cost, technical challenges and risks, and the limited 
access to centers providing intermittent hemodialysis to feline patients the use of this treatment 
modality in feline CKD is limited. 
 
 Prognosis 
A unique clinical aspect of feline CKD is the relatively long period of time (sometimes 
years) without apparent progression of renal dysfunction.  Taking this into consideration, 
prolonged survival is expected in cats with mild to moderate disease (IRIS stage I, II, & early 
III).  Prognostic indicators have been variable and have included the presence of anemia, degree 
of azotemia (plasma creatinine and urea nitrogen), hyperphosphatemia, increased blood 
leukocyte count, and proteinuria.
15,16,29,31,44
  In a recent study cats with stage IIb (creatinine, 2.3-
2.8 mg/dL), III, and IV CKD had median survivals of 1151 days, 679 days, and 35 days, 
respectively.
16
  It is important to note that in this study there was considerable overlap of survival 
times between cats in different IRIS stages.
16
  As such care must be taken when providing a 
prognosis for an individual patient.  At one institution median survival following renal transplant 
was 613 days, with 6 month and 3 year survival rates of 65% and 40%, respectively.
52
  There has 
been no study concerning survival times in cats treated with medical management alone vs. renal 
transplant, thus precluding direct comparisons of these two treatment modalities. 
 
Chapter 2 - Pathophysiology of Chronic Kidney Disease 
 Fibrosis and the Progression of Kidney Disease 
Fibrosis is an exaggerated deposition of extracellular matrix (ECM).  ECM is vital to 
normal organ function facilitating structural support, cellular adhesion and growth, and the 
movement of fluid and macromolecules.
53
  The specific components of ECM is unique to each 
8 
 
organ but includes proteins such as collagen I, collagen IV, fibronectin, laminin, elastin, and 
proteoglycans, amongst others.
53
  In health there exists a balance between matrix deposition and 
degradation.  Fibrosis occurs when matrix deposition exceeds degradation.  ECM is produced by 
multiple cell types including fibrocytes, fibroblasts, and myofibroblasts.  Degradation is 
catalyzed by proteases more specifically plasmin and matrix metalloproteinases (MMP).
53
  
Protease activity can be altered by enzyme inhibitors for example tissue inhibitors of 
metalloproteinases (TIMP) and plasminogen activator inhibitor-1 (PAI-1). 
 
Renal fibrosis is a common end point to essentially all progressive kidney disease, 
including feline CKD.  Renal fibrosis is ECM accumulation in the tubular interstitial 
compartment (tubulointerstitial fibrosis) and glomerulus (glomerulosclerosis).  Histology studies 
have shown that the primary lesion in the majority of feline CKD is located in the tubular 
interstitium.
54
  It is not surprising that feline plasma creatinine concentrations correlate with 
interstitial fibrosis but not with interstitial inflammation, glomerulosclerosis, or renal corpuscular 
diameter.
55
  The fact that the interstitium is primarily affected does not mean that the glomerulus 
escapes undamaged.  Any disease that alters the tubular interstitium also affects the glomerulus 
and vice versa.  Interestingly in people, even when glomerular lesions are considered primary, 
progressive loss of renal function is more closely linked to tubulointerstitial disease.
56
  It is 
important to note that when a portion of the nephron is irreversibly damaged the entire nephron 
is permanently lost. 
 
The list of possible renal insults is long.  In the case of feline CKD, at the time of 
diagnosis a specific underlying cause is rarely identified.  Without an apparent underlying cause 
in the presence of progressive kidney dysfunction a therapeutic dilemma arises.  As discussed 
previously, renal replacement therapy for multiple reasons is uncommonly a feasible option.  
Medical treatment is primarily supportive identifying and treating consequence(s) of renal 
dysfunction as they occur.  As with any disease the identification and treatment of an underlying 
cause is desirable.  Regardless of the underlying etiology tubulointerstitial fibrosis is considered 
by many to be central in the progression of CKD.
57
  There is a paucity of research concerning the 
pathophysiology underlying the progressive decline in renal function in feline CKD.  Partial 
nephrectomy models (one complete nephrectomy and partial infarction of the remaining kidney) 
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in cats have shown morphologic changes but have failed to demonstrate a progressive decline in 
GFR.
58
  The lack of decline in GFR is consistent with what is seen in naturally occurring feline 
CKD, where cats may have stable kidney function for a relatively long period of time.
16,44
  With 
a reduction in the number of functional nephrons compensatory changes occur.  In cats with 
partial renal ablation there was an increase in single nephron GFR due to glomerular 
hypertension and hypertrophy.
59
 In this study single nephron GFR increased not only due to 
increased glomerular filtration pressure but also because of an increased filtration coefficient.
59
  
As an illustration in the ability of the feline kidney to hypertrophy, 4-6 weeks after partial 
nephrectomy the remnant kidney weighed 36% less than the normal kidney despite a 70% 
reduction in nephron number.
59
 One theory, that remains unproven in cats, is that even in the 
absence of the initial underlying insult progressive kidney dysfunction becomes “self-
perpetuating”.58 It has been hypothesized that in mild or moderate CKD, GFR-raising effects 
dominate maintaining stable kidney function but in severe CKD, GFR-lowering effects prevail.
58
  
It is clinically apparent that once azotemia is present, feline CKD is progressive which indicates 
that in the majority of cases at least one of the following scenarios is occurring; (1) the initial 
underlying renal insult is present yet remains unrecognized and/or (2) renal dysfunction 
progresses even in the absence of the initial underlying cause.   
 
One possible scenario to describe the progressive loss of kidney function is that fibrosis is 
not only the result but also the cause of functional nephron loss.  Fibrosis may lead to further 
nephron loss by contributing to; (1) chronic renal hypoxia, (2) alterations in the glomerular 
filtration barrier, and (3) decreased renal cell survival.
57,60-65
  
 
The chronic hypoxia theory first proposed by Fine et al. describes chronic hypoxia as the 
main driving force behind progressive renal disease.
49
  In this theory proteinuria and systemic 
hypertension are “aggravating factors” to progressive renal disease but not causes of progression 
per se.
49
  In this model fibrosis is one of many causes of hypoxia and hypoxia in turns leads to 
further renal parenchymal damage and fibrosis.  Renal fibrosis leads to peritubular capillary 
damage (rarefaction and obliteration) leading to compromised blood flow and renal parenchymal 
hypoxia.
57,64,65
  In response to hypoxia, the renal parenchymal cells alter genotypic expression.  
Most notably, hypoxia inducible factor (HIF), a transcription factor that is known to facilitate the 
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expression of over 100 genes, increases in concentration.
65
  Although protective in acute 
hypoxia, in experimental models of chronic renal hypoxia HIF induces fibrosis.
64
  Numerous 
other causes of renal parenchymal hypoxia have been postulated and include renal anemia, 
altered vascular tone, increased oxygen consumption due to hypertrophy, increased single 
nephron GFR, and oxidative stress.
65
 
 
The hallmark of glomerular disease is proteinuria.  When the glomerular filtration barrier 
is compromised increased concentrations of albumin and other macromolecules enter the 
glomerular ultrafiltrate.  Brenner et al. first described the hyperdynamic theory, which postulates 
that the glomerular hypertrophy and hyperfiltration leads to progressive interstitial disease.
66
 It 
has since been shown that proteinuria and hydrodynamic changes in vitro stimulates the 
production of profibrotic and inflammatory mediators by renal tubular cells.
67-73
  In addition 
human clinical studies have shown that proteinuria is correlated with disease progression and 
that the control of proteinuria slows the decline of kidney function.
23,24,26,74
 Recent work by 
Heymann et al. and Macconi et al. provides the basis for a model that links glomerular disease to 
progressive interstitial disease by means of autoimmunity.
75-77
  In health, albumin and other 
macromolecules that enter the tubule undergo endocytosis by renal tubular epithelial cells that 
then present antigen to dendritic cells (DCs).
77
 Alternatively antigen may be taken up directly 
from the tubular lumen by DCs.
77
  In either case DCs then travel to renal lymph nodes where in 
the healthy kidney cross-tolerance to the presented antigen develops and activated CD8+ T cells 
undergo apoptosis without stimulating an immune response.
78
  In the diseased kidney 
constituents from the damaged renal cells in addition to albumin enter the filtrate and an 
inflammatory response to self antigen ensues leading to inflammation or tubulointerstitial 
nephritis.
75-77
  In this scenario continuous antigenic stimulation leads to perpetual inflammation 
and progressive renal fibrosis and parenchymal damage.  It is noteworthy that as peritubular 
capillaries arise from the glomerular efferent arterioles, glomerular disease may also contribute 
to renal parenchymal hypoxia by decreasing peritubular capillary blood flow.
79,80
  
 
Fibrosis alters ECM composition and three dimensional structure.  ECM is a vital 
component of the structure and function of all parenchymal organs and this fact is most obvious 
in renal fibrosis.  Not only does ECM facilitate three dimensional cellular orientation but ECM is 
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also important for the spatial distribution of cytokines/chemokines, growth factors, and cell 
signaling required for cell survival.
62
 In vitro studies have shown that the specific composition of 
ECM is important for renal cell survival.
60,61
  For example rat mesangial cells, exposed to 
starvation and DNA damage, were protected by collagen IV and laminin whereas collagen I, 
fibronectin, or osteonectin did not improve cell survival.
61
  ECM binding and cell survival 
appears to be β1 integrin mediated.
61
  In addition to composition, three dimensional structure and 
tissue architecture are also crucial to renal cell survival and the maintenance of a differentiated 
phenotype.
63
 
 
Whether progression of CKD results from hypoxia, proteinuria (autoimmunity), or a 
decreased stimulus for cell survival − the common histologic denominator is fibrosis.  
Understanding what precedes fibrosis has therapeutic, diagnostic, and prognostic importance.  
The deposition of fibrous tissue requires a well-coordinated chain of events including: (1) an 
initiating event, (2) release of profibrotic cytokines and growth factors, (3) associated secondary 
sub-cellular signaling, and (4) production of ECM primarily by fibroblasts and myofibroblasts.   
 
The number of people with chronic kidney disease continues to climb with as many as 
6.3% of the population now affected.
81
  In 2008 within the Medicare population the yearly cost 
to treat CKD was $19,752 US per person, which increased with common comorbidities such as 
diabetes and congestive heart failure.
81
  This accounted for 14.2% of all Medicare expenditures.
81
  
For this reason an immense amount of resources is currently being directed toward the 
investigation of novel therapies to slow, stop, or reverse renal fibrosis.  Recognized key 
mediators in renal fibrosis include transforming growth factor β (TGF-β), platelet derived growth 
factor (PDGF), connective tissue growth factor (CCN2), HIF, and RAAS directing key cellular 
events such as: inflammation, autoimmunity, epithelial to mesenchymal transition (EMT), 
hypoxia, and growth arrest and apoptosis.  Therapy intended to slow or reverse tissue fibrosis 
could potentially be directed at any of the aforementioned cellular events and/or mediators.  As 
the fibrotic pathway is complex there are a large number of possible therapeutic targets with the 
caveat being that blocking a single signaling cascade or inhibiting a single fibrotic mediator may 
not substantially alter fibrous tissue deposition.   
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 Transforming Growth Factors β 
Transforming growth factors β (TGF-β) are a family of profibrotic cytokines with anti-
inflammatory and immunoregulatory properties that are instrumental in wound healing and organ 
development and function.
82
  TGF-β expression is upregulated in essentially all naturally 
occurring and induced states of fibrosis.  There are three TGF-β isoforms (1, 2, and 3) all of 
which are expressed in the kidney.
83
  TGF-β1 is the primary isoform produced by mammalian 
cells and is most important in tissue fibrosis.  TGF-β exerts its cellular effects by binding to cell 
surface, transmembrane TGF-β receptors (RI, II, and III).84   Type III receptor, betaglycan, has 
no ability to transduce signal, but rather binds TGF-β and presents it to type II receptors.84 Once 
bound, type II receptors bind type I receptors which are then phosphorylated by type II receptor 
kinases.  TGF-β signals act primarily through the smad pathway.  Smad-independent signaling 
occurs via protein kinase C-δ (PKC-δ) and nonreceptor tyrosine kinase cellular Ableson (c-Abl) 
amongst others.  Eight Smad proteins have been identified in vertebrates.
85
  Smad 2 and 3 are 
phosphorylated in response to TGF-β bound receptors.  Once phosphorylated, smad 2 and 3 bind 
to smad 4.  The resulting smad complex translocates to the nucleus, where it interacts with 
multiple transcription factors, regulating the transcription of pro-fibrotic genes.    Smad 6 and 7 
inhibit phosphorylation of smad 2 and 3 and thereby interfere with transcellular signaling.  In 
addition, internalization in caveolin positive lipid rafts leads to TGF-β receptor degradation and 
is another important regulatory mechanism of TGF-β activity.86,87 Finally the activation of latent 
TGF-β, in response to cell damage or alterations in the cellular micro-environment provides the 
most important means of altering TGF-β function.88 
 
In the kidney TGF-β1 is expressed by mesangial cells, visceral epithelial cells, parietal 
epithelium of the glomerulus, and renal tubular cells.
83
 In addition TGF-β is produced by 
invading cell types including macrophages, monocytes, and platelets.
89
  Initially TGF-β is 
produced in a latent form bound to latency-associated peptide (LAP) which forms the small 
latency complex (SLC).
90,91
  This complex, when bound to latent TGF-β-binding protein (LTBP 
1-4), is known as the large latency complex (LLC).
90,91
  The LLC via LTBP-1 is covalently 
bound to the ECM.
92
  For TGF-β to be biologically active it must dissociate from the LAP.  The 
LLC has been likened to a “molecular sensor” responding to perturbations in the ECM and 
releasing biologically active TGF-β.88  Primarily through interactions with LAP, latent TGF-β 
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can be activated by proteases (plasmin, MMP 2 and 9), thrombospondin-1, integrins (αvβ6 and 
αvβ8), reactive oxygen species (ROS), nitric oxide, and low pH.
93-101
 In addition mechanical 
strain and exposure to elevated glucose concentration or advanced glycation-end products leads 
to increased production of TGF-β.73,102-104  Finally an important stimulator of TGF-β production 
in kidney disease is the RAAS.
105,106
 
 
TGF-β contributes to renal fibrosis by increasing ECM synthesis, decreasing ECM 
degradation, and facilitating cell matrix interactions.
107-110
  TGF-β contributes to ECM in 
multiple ways one of which is the induction of epithelial to mesenchymal transition (EMT).
111,112
  
EMT is the phenotypic transformation of tubular epithelial cells (cytokeratin positive) to 
myofibroblasts expressing smooth muscle actin and/or vimentin.  The phenotypic transformation 
is accompanied by cellular translocation into the interstitium and the production of ECM.
113
  
This phenotypic transition has been demonstrated in vitro and in the dog and rodent.
111,114,115
  
There is evidence that the tubular basement membrane is important for maintaining the epithelial 
phenotype and damage to the basement membrane leads to increased TGF-β and EMT.116  
Although there is a substantial amount of evidence indicating that tubular epithelial cells 
contribute to interstitial fibrosis
112
, recent research has also shown that interstitial myofibroblasts 
may also originate from interstitial perivascular fibroblasts.
117
  In addition to increasing ECM 
production, TGF-β reduces ECM degradation by inhibiting proteases and increasing 
TIMPs.
102,109
 
 CCN2 (Formerly - Connective Tissue Growth Factor)  
There is a multitude of cytokines, growth factors, and other signaling molecules that 
work downstream or in concert with TGF-β to promote fibrosis.  CCN2 is a matricellular protein 
that is important in development, tissue healing, and fibrosis.
118
 Once incorrectly referred to as a 
growth factor, it is now known that CCN2 primarily works by modifying the signaling of other 
molecules and effects of such can vary widely.
118
  In people CCN2 expression is upregulated in 
various kidney diseases and correlates with the degree of tubulointerstitial damage.
119
 The 
production of CCN2 is induced by TGF-β and CCN2 modulates TGF-β activity by decreasing 
smad 7 and increasing smad 2.
120
  In addition cellular stress such as hypoxia can induce the 
production of CCN2.
118
 There is evidence that TGF-β may induce fibrosis but that CCN2 is 
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required to maintain the production of matrix in chronic disease.
121
  In vitro CCN2 increases 
cellular proliferation and the production of fibronectin and type I collagen by renal 
myofibroblast-like cells.
122
  These cellular effects were dependent upon activation of 
extracellular signal-regulated protein kinase (ERK)1/2 mitogen activation protein kinase 
pathway.
122
  The aforementioned profibrotic effects may be partially offset by the fact that in 
vitro CCN2 augments the activity MMP-2 and inhibits TIMP-2.
123
 
 
Chapter 3 - Assessment and Modulation of Renal Fibrosis 
 Clinical Assessment of Fibrosis 
The gold standard of quantifying organ fibrosis involves histologic examination.  
Depending on the patient and the organ, there are times when obtaining an adequate tissue 
sample may not be clinically feasible.  The desire to find non-invasive, reliable, and cost 
effective ways of assessing normal biology, pathologic states, and therapeutic response has led to 
much interest in “biomarkers”.  In regards to biomarkers the kidney is a unique organ in that it 
produces a bodily fluid (urine) that is in sufficient quantity and easily obtained.  Methods of 
quantifying growth factor, cytokine/chemokine, signaling molecules and other proteins or their 
expression in urine has included urine supernatant ELISA and Western blot, urine sediment rt-
PCR, and the analysis of entire urine proteomes via mass spectrometry.  An ideal biomarker is 
one that is safely obtained, rapidly quantitated, and that provides important prognostic, 
diagnostic, or information concerning therapeutic monitoring. 
 
In people urinary TGF-β has been shown to be elevated as compared to normal subjects 
in membranous glomerulonephropathy, mesangial glomerulonephritis, rapidly progressive 
glomerulonephritis, systemic lupus erythematosus, IgA nephropathy, glomerulosclerosis, 
crescentic nephritis, various pediatric renal diseases, nephritic patients, and following renal 
transplant. 
124-130
  In addition urinary TGF-β has been shown to be elevated in feline CKD and 
feline diabetes mellitus.
131
  In this group of cats serum TGF-β concentrations were not increased 
indicating that the urinary TGF-β likely represented local production in the kidney.131  Urinary 
TGF-β mRNA in urine sediment correlated to the amount of interstitial fibrosis and estimated 
GFR in a group of people with IgA nephropathy and glomerulosclerosis.
125
  In addition, urinary 
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TGF-β was shown to be higher in patients with crescentic nephritis that did not respond to 
immunosuppressive therapy as compared to those who did.
127
   
 
Urinary CCN2 concentrations are increased in rats and people with experimentally 
induced renal disease and diabetic nephropathy, respectively.  In addition urinary CCN2 is 
significantly elevated in rodents and humans with histologically confirmed chronic allograft 
nephropathy (interstitial fibrosis and tubular atrophy) following renal transplant.
132,133
  In fact 
urinary CCN2 concentrations increased weeks before serum creatinine and the presence of 
histologic evidence of renal allograft injury.
134
  Although urinary CCN2 concentrations increased 
earlier, when both were present, urinary CCN2 concentrations directly correlated to the amount 
of interstitial fibrosis.
134
  In rats with experimentally induced diabetic nephropathy CCN2 
production originated primarily from the cortex, thus is likely related to glomerular ECM 
accumulation and glomerulosclerosis.
135
 
 
Fibronectin is a major component of ECM and is also found on cell surfaces (cFN) and as 
soluble fibronectin in circulation.
136
  Because the accumulation of ECM accompanies all 
progressive kidney diseases, fibronectin is significantly increased in the renal tissue in essentially 
all human glomerulopathies.
137
  Urinary fibronectin originates from local renal production and 
from systemic circulation (only if the glomerular filtration barrier is compromised).
136
  In people 
with newly diagnosed glomerulonephritis urinary fibronectin concentrations were significantly 
higher in those who had progressive loss of renal function over the subsequent four years as 
compared to those who had non-progressive disease.
136
  In contrast neither proteinuria nor 
systemic blood pressure was higher in this group of people.  Interestingly urinary fibronectin was 
not associated with proteinuria thus indicating that fibronectin was likely produced locally in the 
kidney.  Although in the previous study there was no correlation between urinary fibronectin and 
the severity of glomerular lesions, in a separate human study urinary fibronectin correlated with 
the relative area of interstitial fibrosis.
136,138
  In addition to renal disease urinary fibronectin may 
also be elevated in bladder and urethral cancer and may be utilized to facilitate the initial 
detection and reoccurrence of certain urinary neoplasms.
139,140
  Other constituents of ECM that 
have been quantified in urine include various collagen and collagen fragments.  As measured by 
ELISA, urinary type III collagen was increased in people with diabetic nephropathy.
141
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Interestingly, in a separate study, when quantified via mass spectrometry various collagen 
fragments were decreased in the urine of people with diabetic nephropathy.
142
  This could be 
explained by the decreased ECM degradation that occurs in all progressive kidney disease which 
is at least in part due to the influence of TGF-β.  In this same study the urinary proteome could 
differentiate between diabetic nephropathy and other CKD with 81% sensitivity and 91% 
specificity. 
 
 Other Urinary Biomarkers  
A significant decrease in nephron number deleteriously affects glomerular epithelial 
cells.
143
  Podocytes are unique epithelial cells, which are attached to the glomerular basement 
membrane and are an important component of the glomerular filtration barrier.  Podocyte loss 
contributes to glomerular disease including glomerulosclerosis.  Quantifying podocyte damage 
may include urine sediment cytology detecting podocyturia or by the detection of urinary 
podocyte products.
144-147
  Podocalyxin, a sialomucin, is a cell surface protein expressed by 
podocytes.  In children with glomerular disease, urinary sediment podocalyxin concentration is 
reliable marker for the severity of active glomerular injury.
147
  Other podocyte proteins that have 
been quantified in urine include podocin and nephrin amongst others.
148
 
 
Various other cytokines/chemokines, growth factors, enzymes, and signaling molecules 
have been detected and quantified in urine and include; monocyte chemoattractant factor-1 
(MCP-1), granzyme A, tumor necrosis factor-α (TNF-α), MMP, TIMP, neutrophil gelatinase-
associated lipocalin (NGAL), IL-18, kidney injury molecule-1 (KIM-1), and urinary fatty acid 
binding protein-1 (FABP-1) amongst many others.
149-155
 
 
  Modulating Renal Fibrosis 
The incidence of CKD is growing, as is the need for alternative treatments.
81
  Targeting 
organ fibrosis and more specifically TFG-β and associated mediators of fibrosis has gained much 
attention.  Experimental and clinical therapies that have been investigated with mixed success 
include; RAAS inhibition, anti-TGF-β antibodies, TGF-β anti-sense oligonucleotides, soluble 
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TGF-β co-receptor, smad 7 gene transfer, hepatocyte growth factor (HGF) gene transfer, PKC 
inhibition, tyrosine kinase inhibition, and statin therapy amongst many, many others.
156-162
   
 
Chinese Rhubarb (Rheum palmatum, Rheum officinale), also known as Rheum, has been 
used for thousands of years in traditional Chinese medicine.  Many substances have been isolated 
from rhubarb but the anthraquinones (emodin, rhein, and chrysophanol) and stilbenes 
(resveratrol) have gained the most attention.
163
  In vitro rhein inhibits renal cellular hypertrophy, 
ECM production, and PAI-1 upregulation induced by TGF-β.164,165  In mice with diabetic 
nephropathy rhein corrected dyslipidemias and significantly decreased glomerular hypertrophy 
and ECM expansion via TGF-β inhibition.166  Emodin inhibits the effects of angiotensin II on 
vascular smooth muscle.
167
  In addition emodin has anti-fibrotic properties via the inhibition of 
TGF-β induced collagen production.168  Stilbene derivatives have shown remarkable inhibitory 
effects on lipoxygenase (LOX) and as free radical scavengers.
163
  In rats, with partial 
nephrectomy and adenine induced renal failure, rhubarb extracts decreased glomerulosclerosis, 
renal cell necrosis, proteinuria, and renal values and increased survival.
169,170
  In people with 
CKD, small uncontrolled studies have shown that oral rhubarb administration alleviated uremic 
symptoms and slowed the progression of disease.
171,172
  The most compelling in vivo evidence of 
the anti-inflammatory and anti-fibrotic effects of rhubarb come from people with radiation 
induced lung injury.
173
  In a double-blind, randomized, controlled study people that received 
rhubarb had significantly decreased systemic TGF-β and IL-6 concentrations and radiation 
induced lung injury and significantly improved pulmonary function as compared to placebo.
173
   
 
Chapter 4 - Clinical Study 
 Introduction 
Feline CKD is one of the most common killers of cats and prevalence increases with 
age.
1,2
  Current medical treatment of feline CKD includes the prevention, detection, and 
treatment of the consequences of decreased renal excretory and endocrine function.  Feline CKD, 
after the onset of azotemia, is invariably progressive.  An underlying cause is rarely found at the 
time of diagnosis, which indicates that the cause simply remains undetected or more likely that 
progressive decline in kidney function is self-perpetuating.  Interstitial fibrosis and mononuclear 
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inflammation are common findings in all progressive kidney diseases, including feline CKD.  
There is evidence to support the fact that advanced renal fibrosis is not only the result but may 
also be the cause of progressive CKD.
90,174,175
  Fibrosis may contribute to progressive disease by 
causing renal hypoxia, altering growth signals and cell survival, and leading to a maladaptive 
hyperdynamic state and proteinuria .
49,60,62,65,176
 
 
A treatment that can slow, stop, or reverse renal fibrosis is desirable.  Transforming 
growth factors β are upregulated in essentially all experimentally induced and naturally occurring 
fibrosis, including renal fibrosis.  For this reason TGF-β, associated signaling cascades, and 
downstream mediators of TGF-β are the focus of much research related to renal fibrosis.  
Chinese rhubarb, Rheum palmatum and Rheum officinale, has been used for thousands of years 
to treat various disease in traditional Chinese medicine.  Chinese rhubarb and its constituents 
have been shown to have anti-fibrotic and anti-inflammatory effects in vivo and in 
vitro.
168,170,173,177
  In addition, in rodent models rhubarb supplementation has been shown to 
decrease proteinuria and slow the progression of kidney disease.
170,177
  These effects appear to be 
synergistic with concurrent RAAS blockade.
171,177
  Since 2009 a rhubarb supplement marketed 
toward veterinarians for the treatment of feline and canine kidney disease has been commercially 
available.
178
  The purpose of this study is to investigate the effects of a commercially available 
Chinese rhubarb supplement
a
 on the progression of feline CKD.  The tested hypothesis is that 
Chinese rhubarb extract will slow the progression of feline CKD as compared to benazepril and 
Chinese rhubarb extract and benazepril together will be more effective than either alone. 
 Materials and Methods 
 Cats 
Feline patients were actively recruited from the Kansas State University Veterinary 
Medical Teaching Hospital patient population and from surrounding primary care veterinary 
hospitals.  The study was advertised during continuing education seminars and flyers were 
mailed to referring veterinarians.  Financial compensation was provided to referring veterinarians 
at initial examination and patient inclusion into the study.  Financial compensation was provided 
to the owners at initial visit and after 1 year of participation in the study.  The study in its entirety 
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was approved by the Institutional Animal Care and Use Committee of Kansas State University 
and owner written consent was obtained before patient entry into the study. 
 Inclusion criteria 
Cats were required to have stable IRIS Stage II or Stage III CKD, as diagnosed by a 
serum creatinine of 1.6 – 3.9 mg/dL in a euhydrated state.  Evidence of stable disease by 
demonstrating a less than 20% change in serum creatinine from initial visit to the first follow up 
visit 10-14 days later was required.  In addition cats must not be affected with certain 
comorbidities or consequences of CKD including pyelonephritis, neoplasia, reno- or 
ureterolithiasis, uncontrolled hyperthyroidism, systemic hypertension requiring treatment 
(Doppler >170 mmHg on two occasions or >160 mmHg with evidence of end organ damage), or 
other unrelated disease leading to clinical illness.  The cat was also required to be willing to eat a 
commercially available renal specific diet.
b,h,i
  In addition the patient’s temperament had to be 
such as the required diagnostic evaluation and at home drug administration would not cause 
undue risk to the clinician, student, technical staff, owner, or the cat. Neither the presence nor 
degree of proteinuria was considered an exclusion criterion.  
 Study design 
A prospective, positive-controlled study was conducted.  Cats that fulfilled the inclusion 
criteria were randomly placed into 1 of 3 treatment groups; rhubarb extract (Group 1), 
benazepril
b
 (Group 2), or both (Group 3).  To evaluate drug tolerance rhubarb extract was 
initially administered at 75 mg PO q 24 h.  If well tolerated this dose was increased to 75 mg PO 
q 12 h at 1 month.  Benazepril was administered at approximately 0.5 mg/kg (0.24 mg/lb) PO q 
24 h, with the dose rounded to the nearest ¼ of a 5mg tablet.     
 Screening examination 
Initial diagnostic investigation required to diagnose stable CKD and rule-out comorbid 
diseases included; CBC, chemistry panel, urinalysis with sediment, UPC, species-specific 
semiquantitative urine albumin ELISA
c
, bacterial urine culture, total thyroxine concentration 
(TT4), thoracic radiographs, abdominal radiographs and ultrasound, and Doppler
d
 blood 
pressure.  In addition historical findings, full physical examination, and body weight were 
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recorded.  To facilitate owner compliance all diagnostic examination and treatment was provided 
free of charge. 
 Subsequent examinations 
A repeat examination was scheduled to be performed at 10-14 days at which time if 
stable disease was present the cat was included in the study.  Further examinations were at 1 
month after initial examination and then every 3 months thereafter.  More frequent examinations 
could be scheduled at the discretion of the attending clinician, referring veterinarian, or owner.  
A CBC, chemistry panel, urinalysis with sediment, UPC, species-specific semi-quantitative urine 
albumin ELISA
c
, and Doppler
d
 blood pressure were performed at each examination, excluding 
the CBC which was not performed at the first recheck examination.  In addition a bacterial urine 
culture and TT4 was performed every 6 months and abdominal radiographs and/or ultrasound 
every 12 months.  Finally, historical findings, full physical examination, and body weight were 
recorded at each examination. 
 Blood sample collection and analysis  
Owners were instructed to withhold food but not water for at least 12 hours prior to 
presentation for examinations.  Blood samples were collected from the jugular or medial 
saphenous vein.  Serum biochemical panel, CBC, and TT4 were analyzed on the same day as the 
visit. 
 Urine sample collection and analysis 
Urine samples were collected via cystocentesis.  Urinalysis was performed with a 
refractometer for urine specific gravity, commercially available reagent strip
e
 for chemical 
evaluation, and standard microscopic sediment examination.  A few drops of urine were saved 
from each urine sample and refrigerated until submitted, on the same day, for aerobic culture and 
sensitivity.  Urine protein content was quantified via the benzethonium reaction method and 
urine creatinine was quantified via the buffered Jaffe reaction, both with an automated chemistry 
analyzer
f
.  A UPC ratio was derived from this data for each urine sample.  For individual visits, a 
UPC result was not included in the statistical analysis if any of the following were detected: (1) 
pyuria or >10 WBC/hpf, (2) a  positive bacterial urine culture, (3) gross hematuria, (4) semen, or 
(5) bacteriuria, except for the presence of cocci in the absence of pyuria or a positive urine 
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culture.  In addition, each urine sample was analyzed for microalbuminuria using a commercially 
available species specific urine albumin ELISA by following instructions included in the  
package insert.
c
  Finally, a bacterial urine culture was performed on urine collected via 
cystocentesis at initial visit, every 6 months thereafter, and at the clinician’s discretion.  All urine 
analysis and plating for urine culture was performed on the same day as the visit. 
 Blood pressure measurement 
Systolic blood pressure measurements were obtained by use of an ultrasonic Doppler
d
 
monitor after the cat was acclimated to the hospital environment.  The cat was placed in lateral 
recumbency.  The up leg was used for pressure measurement with a neonatal #2 or #3 cuff 
(width approximately 35-40% the circumference of the leg) placed directly below the elbow.  
After shaving directly over the common digital branch of the radial artery, 3-4 readings were 
obtained and the mean of those readings was recorded. 
 Imaging 
Thoracic radiographs, abdominal radiographs, and abdominal ultrasound were interpreted 
by a board certified veterinary radiologist or a veterinary radiology resident under the direct 
supervision of a board certified radiologist.  When required to achieve diagnostic quality images, 
ketamine (5 mg/kg, 2.2 mg/lb, IV) and diazepam (0.5 mg/kg, 0.23 mg/lb, IV) was administered 
for sedation. 
 Diet 
All cats were exclusively fed a commercially available renal specific diet.  All cats were 
slowly transitioned to a renal specific diet
b
 if not already consuming this diet.  For cats that did 
not accept the first commercially available diet, one of two alternative commercially available 
diets
h,i
 was offered.  To facilitate compliance all diets were provided to the owner free of charge. 
 Treatment 
Clinical management was at the discretion of the attending clinician, but  certain 
guidelines for treatment were established and are described here.  Although hypertension 
requiring treatment was an exclusion criterion, if a cat developed hypertension after inclusion 
into the study, amlodipine
j
 was started at 0.625 mg, total dose, PO q 24 h.  Dose was increased as 
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needed to maintain a systolic blood pressure below 160 mmHg.  Severe hypokalemia was treated 
with intravenous potassium supplementation in the form of potassium chloride.  Mild or 
moderate hypokalemia was treated on an outpatient basis when the potassium fell below the 
reference interval.  Potassium gluconate in powder, tablet, or gel form was prescribed at 2 mEq, 
total dose, PO q 12h. This dose was increased as needed to maintain serum potassium within the 
normal range.  Enteric phosphate binders were prescribed when serum phosphorous was found to 
be above the reference interval and the cat had been fed exclusively a renal specific diet for at 
least 1 month.  Enteric phosphate binders prescribed included aluminum hydroxide
k
 or Epakitin
l
.  
Enteric phosphate binders were given with food twice daily and dose was increased as needed to 
maintain a serum phosphorous within the reference range.  If a cat was previously receiving sub-
cutaneous fluids at inclusion in the study this treatment was continued.  Cats that were found to 
be chronically clinically dehydrated, and deemed good candidates by the clinician and owner, 
were administered sub-cutaneous fluids with the dose determined on a case by case basis.  
Bacterial urinary tract infections were treated with an appropriate antibiotic based on culture and 
sensitivity testing.  Treatment outcome was based on clinical signs and a repeat bacterial culture 
within 1 week of discontinuing antibiotic treatment.  Uremic crisis and other illness not 
necessarily related to CKD were treated on a case by case basis at the discretion of the owner and 
attending clinician.  To facilitate compliance all treatment(s) including uremic crisis and illness 
unrelated to CKD was provided free of charge to the owner. 
 Cause of death 
Renal-related death (RD) was defined as death or euthanasia due to the progressive 
decline of renal function or the consequences thereof.  This classification required 
documentation of an increased serum creatinine and clinical signs associated with azotemia 
including but not limited to anorexia, weight loss, gastrointestinal upset,  and lethargy.  Non-
renal-related death (NRD) was defined as a documented cause of death or euthanasia, in which 
there was not a substantial increase in serum creatinine and/or an unrelated disease process was 
determined to play a substantial role in the patient’s demise.  All cause death (ACD) includes 
both RD and NRD. 
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 Statistical analysis 
Statistical analyses were performed on commercial software.
m,n
  Descriptive statistics are 
presented at mean ± SD.  Body weight, hematocrit, blood pressure, serum creatinine, and UPC 
were compared between groups at enrollment with ANOVA.  In addition mean time of study 
enrollment was compared between groups with ANOVA.  When appropriate a Sidak post hoc 
correction for multiplicity was used. Change in body weight, hematocrit, blood pressure, serum 
creatinine, and UPC were compared within groups and between groups over time with repeated 
measures ANOVA.  Cats with less than four hospital visits as participants in the study, only due 
to recent inclusion into the study, were not included in the statistical analysis.  Otherwise all 
participants were included in the statistical analysis.  Significance was set at p≤ 0.05. 
 
Target study numbers were based on a pre-study power estimate.  It was estimated (based 
on expected population variance, mean, significant difference, and a within patient correlation of 
0.75) that 6 cats in each group would detect a difference in serum creatinine of 0.4 mg/dL, UPC 
of 0.14, and systolic blood pressure of 10 mmHg at a power of 0.80.  In other words there would 
be a 20% chance of a type II error or failing to detect a significant difference between or within 
treatment groups when in fact one exists. 
 Results 
A total of 46 cats were evaluated as possible participants in the study.  Seventeen of these 
were excluded because of failure to fulfill inclusion criteria, specifically due to an inappropriate 
degree of azotemia (n=6 cats),  systemic hypertension that required specific medical treatment 
(n=5),  reno- or ureterolithiasis (n=3), illness from disease deemed not to be related to CKD 
(n=2), and fractious nature (n=1).  The remaining 29 cats were enrolled in the study.  Three cats 
that were enrolled in the study were not included in statistical analysis because of having less 
than four hospital visits as a participant in the study, due to recent inclusion, at the time of 
writing.  Of the remaining cats, 8 cats were allocated to the rhubarb only group (Group 1), 9 cats 
to the benazepril only group (Group 2), and 9 cats to the rhubarb and benazepril group (Group 
3).  One cat originally allocated to Group 2 had a presumed severe cutaneous drug reaction to 
benazepril soon after inclusion into the study.  This cat was placed in Group 1 after a 30 day 
“washout” period. 
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There were no significant differences between treatment groups at entry into the study for 
blood pressure, hematocrit, serum creatinine, or UPC (Table 1).  There was a significant 
difference in body weights between group 1 and group 3 (5.65 ± 1.18 kg and 3.49 ± 1.13 kg, 
respectively; P = 0.023).  The mean ± SD duration of time that cats were enrolled in the study, at 
time of statistical analysis for all cats was 17.0 ± 8.3 months (Table 3).  The mean ± SD duration 
of enrollment for Group I, II, and III are 16.8 ± 9.78, 18.9 ± 8.52, and 15.1 ± 6.40 months, 
respectively (Table 3).  There were no significant differences within groups over time for blood 
pressure, hematocrit, serum creatinine, change in body weight, or UPC (Figures 1-5).  There 
were no significant differences between groups over time for blood pressure, hematocrit, serum 
creatinine, change in body weight, or UPC (Figures 1-5). 
 
While enrolled in the study five cats died or were euthanized due to renal-related reasons.  
The number of cats from Group I, II, and III were one, 2, and 2, respectively.  An additional 4 
cats died or were euthanized unrelated to renal disease.  The number of cats from Group I, II, and 
III were 2, none, and 3, respectively.  Cause of death in this group of cats included 2 cats 
euthanized due to persistent inappropriate elimination, one cat with renal transitional cell 
carcinoma, and one cat with pancreatic carcinoma.  One cat died of unknown causes.  Based on 
contemporaneous blood work and clinical signs this death was determined to be non-renal-
related.  The number of AD cats in Groups I, II, and III were 3, 2, and 5, respectively.  The mean 
duration between entry into the study and RD, NRD, and AD was 19.0 ± 4.56, 11.6 ± 4.03, and 
15.3 ± 5.68 months, respectively (Table 2).  Due to the low rate of mortality, survival analysis 
was not performed. 
 Discussion 
This study is the first to investigate the effects of a commercially available rhubarb 
extract
a
 on the progression of naturally occurring feline CKD.  Feline CKD is the result of a 
predictable renal response to a heterogeneous group of renal insults.  Likewise any given group 
of cats affected with CKD will be widely variable with regards to many parameters including: 
signalment, comorbidity, degree of renal dysfunction, and the consequences of said renal 
dysfunction.   
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The diagnosis of feline CKD is essentially one of exclusion.  Azotemia due to ureteral 
obstruction, renal neoplasia, pyelonephritis, pre-renal or other post-renal causes must be ruled-
out.  The diagnosis usually includes small irregular kidneys on abdominal palpation and small, 
irregular kidneys with a loss of corticomedullary definition on abdominal ultrasound.  It should 
be noted that this diagnosis usually does not include renal biopsy.  As such it is possible for a 
specific underlying  etiology to go undetected.  One cat in this study was found to have renal 
transitional cell carcinoma on post-mortem examination.  Although it is possible that this 
neoplasm was the cause of renal dysfunction in this patient from the beginning, it is also possible 
that this cat developed renal transitional cell carcinoma subsequent or in addition to feline CKD.  
The fact that this cat lived for almost 11 months with essentially stable renal function, that renal 
imaging was consistent with CKD at inclusion, and post-mortem examination showed both 
glomerulosclerosis and interstitial nephritis in addition to transitional cell carcinoma make the 
latter scenario more likely.  For these reasons this cat was included in the final statistical 
analysis.   
 
The results of this study failed to find any significant difference between treatment with 
rhubarb extract, benazepril, or both in regards to the progression of CKD as quantified by serum 
creatinine, hematocrit, change in body weight, systemic blood pressure, and UPC.  One 
limitation to this study is that GFR, being a direct measure of renal excretory function was not 
measured.  Instead serum creatinine was used.  Serum creatinine indirectly correlates with GFR 
when certain factors such as body weight are held stable.
179
  As a whole group the cats in this 
study, were expected to lose body weight over time.  Although Group 1 cats had a significantly 
greater body weight than Group 3 cats at inclusion, there was no significant difference in the 
change in body weight over time between groups, indicating that across groups the effect of the 
change in body weight as it pertains to serum creatinine concentrations would be similar.   
 
In this study with the use of client owned cats, and with client compliance in mind, 
repeated measurement of GFR was considered infeasible and unjustified.  Other variables such 
as serum creatinine, change in body weight, hematocrit, systemic blood pressure, and UPC were 
chosen as these represent variables commonly affected by the loss of renal function..  Body 
weight is an important clinical variable as a combined indication of appetite and the catabolic 
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state of chronic uremia.  This variable is likewise important to owners as a loss of lean body 
mass is easily observed and perceived negatively with regards to the patient’s quality of life.  
There were no attempts in this study to further characterize loss of body weight in relation to 
caloric intake or lean body mass.   
 
Hematocrit was chosen as an indication of renal endocrine function.  Although renal 
excretory function is commonly considered when dealing with chronic kidney disease, endocrine 
dysfunction in the case of a relative lack of erythropoietin can provide important therapeutic and 
prognostic information.
15,31
  The failure to detect and appropriately treat anemia of CKD leads to 
lethargy and other signs of systemic illness readily recognized by the owner.  It is accepted that 
anemia associated with CKD is multifactorial.  In this study early signs of anemia especially 
when accompanied by gastric upset were treated with gastric acid suppression usually in the 
form of famotidine.  While this treatment was directed towards gastric erosion or ulceration that 
may develop secondary to hypergastrinemia no further investigation such as gastric endoscopy 
was used to corroborate or refute this assumption.  In addition bone marrow sampling in order to 
further investigate non-regenerative anemia was not performed in any cat.  For this reason, 
although assumed to be unlikely, an undiagnosed comorbidity may have affected the hematocrit.  
An alternative to measuring hematocrit would have been quantifying erythropoietin directly, 
which would have been interpreted in light of the patient’s hematocrit.  At the time of this study 
a commercial erythropoietin assay was not available. 
 
Systemic hypertension is a clinically important sequela- to feline CKD.  As such, 
systemic blood pressure was monitored throughout the study.  There is no evidence to support 
the fact that systemic hypertension is more prevalent as CKD progresses.  In addition, there is no 
evidence that systemic hypertension negatively affects the prognosis associated with feline CKD.  
In fact there is evidence that any benefit to survival with regards to the control of systemic 
hypertension is actually related to the subsequent decrease in proteinuria.
30
  With that being said 
the consequences of systemic hypertension including cardiomyopathy and acute blindness may 
indirectly affect survival in an individual patient.  Certainly acute blindness is easily noticed by 
the owner and may lead to euthanasia.  For this reason systemic hypertension that required 
specific medical management, as defined above, was an exclusion criterion. Making systemic 
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hypertension an exclusion criterion likely selected for a population of cats that were much less 
likely to develop systemic hypertension thereafter which may have contributed to finding 
insignificant changes in mean systemic blood pressure between and within treatment groups over 
time. 
 
 Quantification of urine protein concentration or the UPC provides prognostic 
information in feline CKD.
15,30,31
  As such it would have been reasonable to either stratify or 
include a specific UPC as an exclusion criterion.  The inclusion of proteinuric cats was deemed 
important as studies concerning rodent models of kidney disease have shown a decrease in urine 
protein content with the administration of rhubarb extract.
170,177
  Cats seem less likely to have 
overt proteinuria associated with kidney disease when compared to dogs and humans, although 
this has not been directly investigated in any one study.  In the 29 cats included in this study only 
8 cats had a UPC > 0.2 and only 1 cat had a UPC > 1.0 at inclusion.  It could be postulated that 
the infrequent severe proteinuria is in part responsible for the slow or clinically silent decline in 
renal function over long periods of time in this species.  In attempts to ensure proteinuria was of 
renal origin, urine samples with pyuria, bacteriuria, gross hematuria, positive bacterial urine 
culture, or semen were excluded from statistical analysis. 
 
Another limitation to this study is the length of time cats were enrolled in the study.  The 
mean duration of enrollment for all cats in this study at the time of writing was approximately 17 
months.  As stated earlier 5 cats died of renal causes and 5 cats died of non-renal causes.  At the 
time of writing, 9 additional cats had withdrawn from the study (not due to death/euthanasia).  
The most common reason for withdraw was owner relocation, which like most other reasons for 
study withdraw are inherent to long clinical studies.  One cat was removed from the study due to 
acute ureteral obstruction and acute exacerbation of azotemia.  This cat underwent successful 
treatment with ureterotomy and urolithectomy.  At the time of writing, 9 cats were still active in 
the study.  For case recruitment, referring veterinarians received a monetary incentive as did 
owners.  The fact that a portion of the monetary incentive was given after 1 year of enrollment in 
the study likely improved compliance and participation in the study.  Due to the monetary 
incentives provided, compliance as it relates to the individual treatments could not be 
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investigated.  No attempts were made to assess owner compliance beyond questioning during 
obtaining historical information at each visit. 
 
As expected, cats with IRIS Stage II or III CKD live a long time.  It was for this reason 
that alternative dependent variables such as serum creatinine and hematocrit were used to assess 
response to treatment.  In many countries, death associated with feline CKD is commonly due to 
euthanasia, usually due to a perceived poor quality of life.
10,15,16,44
  This was shown in this study 
as all deaths were due to euthanasia.  Out of the 5 cats that died due to non-renal-related causes, 
2 were euthanized due to persistent inappropriate urination or periuria.  It could be argued that 
this was related to CKD as these cats are polyuric.  Other comorbidity, whether related to CKD 
or not, that might predispose a cat to periuria includes urinary tract infection, osteoarthritis, or 
cognitive dysfunction.  Both cats had multiple negative bacterial urine cultures making bacterial 
cystitis an unlikely cause.  Osteoarthritis was believed to be present in one case based on crepitus 
during joint manipulation.  This cat failed to improve upon provision of an additional litter box 
that did not require a step-up and medical treatment for osteoarthritis.  It was possible that 
osteoarthritis or the reluctance to step-up into the litter box initiated the periuria which then 
became behavioral, in which case treatment of the osteoarthritis may not lead to improvement.  
Cognitive dysfunction was believed to play a role in the second cat’s periuria although this was 
at best speculative.  Because other disease likely played a substantial role in the periuria and 
subsequent euthanasia in both cats they were classified as non-renal-related deaths.  To 
investigate the effect of treatment as it relates to renal-related death in a study of this nature 
would require a substantially longer study duration, larger study population, or inclusion of cats 
with more advanced kidney disease. 
 
It should be noted that not finding a significant difference between treatment groups is 
only notable with an appropriately powered study.  Pre-study power estimates showed that 
including 6 cats in each group would provide a power of 0.80 for the detection of a 0.4 mg/dL 
difference in serum creatinine, a 0.14 difference in UPC, or a 10 mmHg difference in systemic 
blood pressure.  Differences in these variables to this degree were considered clinically relevant.    
This was assuming an intra-cat correlation over time of 0.75.  This study consisted of at least 8 
cats per treatment group.  As such there is expected to be at least an 80% chance that if a 
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significant difference existed it would have been detected.  With a β of anything but 1.0 there 
will always be a chance of not detecting a significant difference when one truly exists.  When 
considering the comparison between two or more treatments, the only way of increasing β is to 
increase study number or decrease population variance (considering a certain dependent 
variable).  To allow this population of cats to represent the domestic cat population as a whole, a 
certain degree of variability was necessary.  There was no attempt to make post-study power 
estimates. 
 
It has been suggested that an ACEi may slow the progression of feline CKD, although the 
evidence is minimal.
20,21
  As previously discussed there is certainly evidence in other species that 
this is the case.
106,156,180-182
  Not finding a significant difference between treatment groups would 
indicate that in this population of cats both benazepril and rhubarb extract affected the 
progression of CKD to the same degree (or possibly not at all).  Rhubarb extract has been shown 
to decrease proteinuria in experimentally induced kidney disease in various rodents.
170,177
  
Alhough proteinuria was ucommon, the authors felt it was unethical to withhold appropriate 
treatment of proteinuria, acknowledging that evidence supporting the use of an ACEi in feline 
CKD remains minimal.  In addition there is evidence that the therapeutic effects of an ACEi and 
rhubarb as they affect proteinuria and renal fibrosis act synergisticly.
170,177
 For these reasons 
benazepril was chosen as the positive control and a third group of cats administered both drugs 
was included in the study.    Without a negative control it is impossible to make any statement 
with regards to how either treatment compared to no treatment at all.  Because neither owners 
nor investigators were blinded to the treatment groups some treatment bias is expected.  The 
objective measures of kidney function or consequences thereof, such as serum creatinine, 
hematocrit, change in body weight, systemic blood pressure or UPC likely were not affected by 
this bias.  Alternatively, it is safe to assume that the owner’s perceived quality of life and the 
knowledge of lab values may have influenced the decision to euthanize for renal or non-renal 
related reasons. 
 
Possible side effects of the rhubarb extract and benazepril were noted at each hospital 
visit as determined by historical findings provided by the owner and physical exam and 
laboratory findings.  Two cats in Group 1 had reported possible side effects that included 
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transient lethargy and gastrointestinal upset.  One cat in Group 2 had what appeared to be a 
severe cutaneous drug reaction which manifested as widespread erythema, pruritis, and alopecia 
most severe on the ventrum.  Skin scrape and cytology were unremarkable.  No further 
diagnostic investigation such as skin biopsy was performed.  The apparent cutaneous reaction 
mostly resolved over the next 2 weeks after discontinuation of benazepril administration.  
Because this cat fit all inclusion criteria and had begun the study, at the owners request the cat 
was switched to Group 1.  The fact that this group change contradicted the goals of random 
allocation was recognized, although the effect to the overall randomness of the study was 
considered minor.  A total of 17 cats in this study received rhubarb extract for a mean duration of 
15.9 ± 7.7 months.  The fact that only 2 cats showed mild findings that were possibly associated 
with rhubarb administration would indicate that Rubenal
®
 is safe to administer over a long period 
of time to cats with stage II or III CKD.  It should also be noted that only one owner reported 
difficulty in administering the Rubenal
®
 tablet. 
 Conclusion 
The commercially available Chinese rhubarb extract (Rubenal
®
) is safe when 
administered to cats with Stage II or III CKD.  In the studied population of cats, based on the 
analysis of easily measured clinical indicators of renal exocrine and endocrine function, this 
study failed to find a significant difference in the progression of feline CKD between cats 
administered oral benazepril, Rubenal
®
, or both at recommended doses.  Further investigation 
into the effects of rhubarb extract as it relates to specific subsets of the cat population affected 
with CKD and as compared to no treatment may be indicated. 
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 Footnotes 
 
a. Rubenal, Vetoquinol USA, Fort Worth, TX 
b. k/d, Hill’s Pet Nutrition, Topeka, KS 
c. Benazepril, Teva Pharmaceuticals USA, North Wales, PA 
d. E.R.D. Health Screen Urine Tests, Heska, Loveland, CO 
e. Ultrasonic Doppler Flow Detector, Parks Medical Electronics Inc., Aloha, OR 
f. Bili Labstix, Bayer Healthcare LLC., Morristown, NJ 
g. Hitachi 911, Roche Diagnostics, Indianapolis, IN 
h. NF Kidney Function, Purina Veterinary Nutrition, St. Louis, MO 
i. Renal LP, Royal Canin USA, St. Charles, MO 
j. Amlodipine, Mylan Pharmaceuticals Inc., Canonsburg, PA 
k. Aluminum hydroxide, Rugby Laboratories Inc., Corona, CA 
l. Epakitin, Vetoquinol USA, Fort Worth, TX 
m. STATA 11, STATA Corp LP, College Station, TX 
n. SAS on Demand, SAS, Cary, NC 
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Figures 
 Figure 1. Serum creatinine by treatment and visit. 
 
 
A chart of serum creatinine concentrations (mg/dL) over time.  Solid lines are group means and 
dotted/dashed lines are 95% confidence intervals.  There was not a significant difference over 
time between or within groups. 
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 Figure 2. Indirect blood pressure by treatment and visit. 
 
 
A chart of systolic blood pressure over time.  Solid lines are group means and dotted/dashed 
lines are 95% confidence intervals.  There was not a significant difference over time between or 
within groups. 
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 Figure 3. Urine protein creatinine ratio by treatment and visit. 
 
 
A chart of UPC over time.  Solid lines are group means and dotted/dashed lines are 95% 
confidence intervals.  There was not a significant difference over time between or within groups. 
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 Figure 4. Change in body weight by treatment and visit. 
 
 
A chart of change in body weight (kg) over time.  Solid lines are group means and dotted/dashed 
lines are 95% confidence intervals.  There was not a significant difference over time between or 
within groups. 
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 Figure 5. Hematocrit by treatment and visit. 
 
 
A chart of change in body weight over time.  Solid lines are group means and dotted/dashed lines 
are 95% confidence intervals.  There was not a significant difference over time between or 
within groups. 
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Tables 
 Table 1. Select parameters at study inclusion 
Variable Overall mean ± SD P-value 
Serum creatinine (mg/dL) 2.43 ± 0.66 0.887 
Indirect blood pressure (mmHg) 129 ± 16.5 0.173 
UPC 0.54 ± 1.11 0.656 
Hematocrit (%) 34.5 ± 5.91 0.390 
Body weight (kg) 
Group 1 vs. Group 3 
Group 1 vs. Group 2 
Group 2 vs. Group 3 
4.67 ± 1.65 0.022 
0.021 
0.592 
0.125 
 
There were no difference between groups at entry into the study for serum creatinine, indirect 
blood pressure, UPC, or hematocrit.  Group 1 cats weighed significantly more than Group 3 cats. 
 
 
 Table 2. Duration time to death 
Cause of death Overall time from inclusion to death 
(months, mean ± SD) 
Renal related death (RD) 19.0 ± 4.56 
Non-renal related death (NRD) 11.6 ± 4.03 
All cause death (AD) 15.3 ± 5.68 
 
The overall time from inclusion into the study to death for all cats included in the study.  Due to 
a relatively low mortality rate statistical analysis was not attempted. 
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 Table 3.  Duration of enrollment 
Group Duration (months, mean ± SD) P-value 
Group 1 (rhubarb only) 17.0 ± 9.78  
0.631 Group 2 (benazepril only) 18.9 ± 8.52 
Group 3 (both) 15.11 ± 6.39 
All groups 17.0 ± 8.28  
 
There was no significant difference in enrollment time between groups. 
 
 
 
 
54 
 
Appendix A – IRIS Staging Schemes 
a. IRIS staging scheme for feline CKD*
5
 
IRIS Stage Plasma Creatinine (mg/dL) Comments 
I <1.6 No clinical signs 
II 1.6-2.8 Usually no clinical signs 
III 2.9-5.0 May have clinical signs 
IV >5.0 Clinical signs present 
*Proteinuria and systemic hypertension or lack of is noted as sub-stages. 
 
b. IRIS systemic blood pressure risk scheme
5
 
IRIS Stage Systolic BP (mmHg) Diastolic BP (mmHg) 
0 – minimal risk <150 <95 
1 – low risk 150-159 95-99 
2 – moderate risk 160-179 100-119 
3 – high risk >180 >120 
 
c. IRIS proteinuria staging scheme
5
 
UPC Value Sub-stage 
<0.2 Non-proteinuric (NP) 
0.2-0.4 Borderline proteinuric (BP) 
>0.4 Proteinuric (P) 
 
 
 
